Equity Details
Price & Market Data
Price: $4.49
Daily Change: -$0.05 / 1.11%
Daily Range: $4.49 - $4.62
Market Cap: $631,279,808
Daily Volume: 627,674
Performance Metrics
1 Week: -2.45%
1 Month: 9.17%
3 Months: 43.28%
6 Months: 95.77%
1 Year: 258.2%
YTD: 52.33%
About Aclaris Therapeutics, Inc. (ACRS)
Track Aclaris Therapeutics, Inc. (ACRS)'s latest movements. Priced at 4.49, the stock has a daily change of -$0.05 / 1.11%. Its market cap stands at 631,279,808. Gain insights from its 1-year performance (258.2%) and YTD results.
Company Details
Employees: 73
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
